Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Mesoblast Limited (MESO) Price & Performance

BioNTech SE - ADRTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Mesoblast Limited — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: BioNTech SE - ADR is far larger — about 10.5× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXMESO
Market Cap
$23.31B$2.21B
Sector
HealthTechnology
52-Week High
$119.34$20.96
52-Week Low
$83.89$12.88
Enterprise Value
$6.60B$2.21B

Returns comparison

Trailing returns across standard periods

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO